objective responses (ORR)

la/mBC - HR positive - L2 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - PIK3CA mutant

versus fulvestrant
buparlisib plus fulvestrant vs. fulvestrant 1 certainty unassessable+34%